<DOC>
	<DOCNO>NCT00616798</DOCNO>
	<brief_summary>This study determine efficacy safety RO4917838 patient schizophrenia stable current antipsychotic treatment ( olanzapine , que tiapine , risperidone , paliperidone aripiprazole ) prominent negative isorganized thought symptom . After 4 week run period current anti psychotic treatment , patient randomize receive placebo 10mg , 30mg , 60mg RO4917838 daily , p.o. , add-on therapy . The anticipated time n study treatment &lt; 3 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study RO4917838 Combination With Antipsychotic Treatment Patients With Schizophrenia .</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>adult patient , 1860 year age ; diagnosis schizophrenia ( base screening test ) ; outpatient , hospitalization worsen schizophrenia within 3 month ; medically psychiatrically stable prior 1 month psychiatrically stable without symptom exacerbation within prior 3 month ; currently take 2 antipsychotic drug . begin new nonmedication treatment schizophrenia psychiatric condition within last 3 month ; &gt; 1 antidepressant , change dose antidepressant within 3 month ; alcohol substance abuse dependence within 3 month ; previously receive RO4917838 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>